Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
E
E
Lierman
S
S
Smits
J
J
Cools
B
B
Dewaele
M
M
Debiec-Rychter
P
P
Vandenberghe
D000818:Animals; D001549:Benzamides; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000494:pharmacology*; D051379:Mice; D009154:Mutation / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010879:Piperazines / Q000009:adverse effects*; D054448:Precursor Cells, B-Lymphoid / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011724:Pyridazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000009:adverse effects*; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000235:genetics*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
D001549:Benzamides; D007093:Imidazoles; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; C545373:ponatinib; D000068877:Imatinib Mesylate; C496348:FGFR1 protein, human; C479819:FIP1L1-PDGFRA fusion protein, human; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D051496:Receptor, Fibroblast Growth Factor, Type 1; D020796:Receptor, Platelet-Derived Growth Factor alpha